Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Task Force Supports Formerly Controversial Statin Guidelines

December 23, 2015 By Lauran Neergaard, Associated Press

Considering a cholesterol-lowering statin to prevent a heart attack? Deciding who’s a good candidate requires calculating more than a simple cholesterol level.

A government task force says the popular medications will be of most benefit to some people ages 40 to 75 whose risk of cardiovascular disease over the next decade is at least 10 percent. But Monday’s draft guidelines from the U.S. Preventive Services Task Force left some wiggle room, saying certain patients who aren’t at quite as high a risk still might benefit and should weigh the pros and cons for themselves.

“The benefit from statins is going to be the largest in the people who are at the highest risk,” explained Dr. Douglas Owens, a Stanford University professor and task force member.

The recommendations are similar to controversial 2013 guidelines from the American Heart Association and American College of Cardiology.

Calculating Risk 

The task force endorsed usage of an online calculator available through the American Heart Association’s web site.

Doctors plug in information about the patient’s age, sex, race and other health conditions in addition to the level of LDL cholesterol, the so-called bad kind. That’s because recent research shows the combination of factors is particularly important — that someone who might not have qualified for statins on the basis of an LDL level alone could benefit if other factors raise their overall risk.

“We recommend that people between 40 and 75 have an assessment of their cardiovascular risk and that’s not just triggered by your cholesterol,” Owens said.

Other Guidelines 

The 2013 guidelines from the heart association and college of cardiology recommended that doctors consider statins in people ages 40 to 75 whose 10-year risk is 7.5 percent or higher. Those guidelines were controversial because they made millions more Americans eligible for statins than older recommendations that focused more on cholesterol levels.

While Monday’s task force conclusion was that people at higher risk get more benefit, the two sets of advice are consistent, said American Heart Association spokesman Dr. Donald Lloyd-Jones of Northwestern University.

Monday’s recommendations are open for public comment through January 25.

Related Articles Read More >

Medtronic Hugo robot-assisted surgery system
The road to a robot: Medtronic’s development process for its Hugo RAS system
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A portrait of Stryker executive Tracy Robertson
Stryker leaders talk medtech trends at DeviceTalks Boston: ‘If you’re slow, you’re going to lose’
gBETA Medtech accelerator picks its next startups

DeviceTalks Weekly.

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech